Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in
Biomerk Tumorgrafts(TM)
BALTIMORE, Oct. 26 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc.
(OTC Bulletin Board: CSBR), a company with a predictive preclinical platform
aimed at accelerating the development and enhancing the value of oncology
drugs, has established an agreement with Ortho Biotech Oncology Research &
Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a
novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM)
platform.
"We are excited to expand this ongoing collaboration in the development of
innovative therapeutics in oncology," said Doug Burkett, Ph.D., President of
Champions Biotechnology, Inc. "We continue to grow our customer base and
revenues within our Preclinical eValuation business. Our Biomerk Tumorgraft
models offer a more predictive preclinical platform to enhance and accelerate
oncology drug development. Evaluations in our Tumorgraft models are expected
to enable the identification of the most promising development path by
focusing on indication, drug combinations, target patient populations and
biomarker discovery."
For more information regarding Champions Biotechnology's growing business and
recent news, please visit www.championsbiotechnology.com.
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and tumor specific data to enhance and accelerate the
value of oncology drugs. The Company's Preclinical Platform is a novel
approach based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological characteristics of
the original human tumor. Early studies suggest that unlike traditional
xenografts, these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates. As
drugs progress through early stage development, the Company plans to sell,
partner or license them to pharmaceutical and/or biotechnology companies, as
appropriate. The Company also offers its predictive preclinical platform and
tumor specific data to physicians for personalized patient care and to
companies for evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
www.championsbiotechnology.com
www.personalizedcancertreatment.com
This press release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan,"
and similar expressions to identify forward-looking statements. One should not
place undue reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the forward-looking
statements for many unforeseen factors. See Champions Biotechnology's Form
10-K for the fiscal year ended April 30, 2009 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.
CONTACT:
The Investor Relations Group, Inc.
James Carbonara
+1-212-825-3210
SOURCE Champions Biotechnology, Inc.
James Carbonara, The Investor Relations Group, Inc., +1-212-825-3210
